Bristol-Myers Squibb (NYSE:BMY) Shares Acquired by Vest Financial LLC

Vest Financial LLC boosted its position in Bristol-Myers Squibb (NYSE:BMY - Free Report) by 73.5% in the 1st quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 16,912 shares of the biopharmaceutical company's stock after purchasing an additional 7,166 shares during the quarter. Vest Financial LLC's holdings in Bristol-Myers Squibb were worth $1,031,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in BMY. Vanguard Group Inc. lifted its stake in shares of Bristol-Myers Squibb by 0.7% in the fourth quarter. Vanguard Group Inc. now owns 189,944,516 shares of the biopharmaceutical company's stock worth $10,743,262,000 after buying an additional 1,373,209 shares in the last quarter. Capital International Investors lifted its stake in Bristol-Myers Squibb by 7.5% in the 4th quarter. Capital International Investors now owns 45,866,624 shares of the biopharmaceutical company's stock worth $2,593,940,000 after purchasing an additional 3,218,865 shares in the last quarter. Geode Capital Management LLC lifted its stake in Bristol-Myers Squibb by 2.7% in the 4th quarter. Geode Capital Management LLC now owns 44,391,247 shares of the biopharmaceutical company's stock worth $2,505,967,000 after purchasing an additional 1,187,231 shares in the last quarter. Norges Bank acquired a new position in shares of Bristol-Myers Squibb during the 4th quarter worth approximately $1,989,525,000. Finally, Ameriprise Financial Inc. grew its position in shares of Bristol-Myers Squibb by 59.9% in the fourth quarter. Ameriprise Financial Inc. now owns 32,079,246 shares of the biopharmaceutical company's stock valued at $1,814,341,000 after purchasing an additional 12,011,983 shares in the last quarter. Hedge funds and other institutional investors own 76.41% of the company's stock.

Analyst Upgrades and Downgrades

A number of equities analysts recently commented on BMY shares. UBS Group reduced their price objective on Bristol-Myers Squibb from $60.00 to $54.00 and set a "neutral" rating on the stock in a research report on Friday, April 11th. William Blair reiterated a "market perform" rating on shares of Bristol-Myers Squibb in a report on Friday, April 25th. Piper Sandler began coverage on shares of Bristol-Myers Squibb in a report on Tuesday, April 22nd. They issued an "overweight" rating and a $65.00 price objective for the company. Jefferies Financial Group decreased their target price on shares of Bristol-Myers Squibb from $70.00 to $68.00 and set a "buy" rating on the stock in a report on Wednesday, April 23rd. Finally, The Goldman Sachs Group reiterated a "neutral" rating and issued a $55.00 price objective (down from $67.00) on shares of Bristol-Myers Squibb in a report on Tuesday, April 8th. Two investment analysts have rated the stock with a sell rating, thirteen have assigned a hold rating, six have assigned a buy rating and two have assigned a strong buy rating to the company. According to data from MarketBeat, Bristol-Myers Squibb has an average rating of "Hold" and a consensus price target of $58.00.

Insiders Place Their Bets

In other Bristol-Myers Squibb news, EVP Samit Hirawat purchased 4,250 shares of the firm's stock in a transaction on Friday, April 25th. The stock was bought at an average cost of $47.58 per share, with a total value of $202,215.00. Following the acquisition, the executive vice president now directly owns 83,513 shares of the company's stock, valued at approximately $3,973,548.54. This represents a 5.36% increase in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. 0.09% of the stock is currently owned by company insiders.

Bristol-Myers Squibb Stock Up 1.0%

Shares of Bristol-Myers Squibb stock traded up $0.52 during trading hours on Thursday, reaching $50.68. 9,595,506 shares of the company were exchanged, compared to its average volume of 13,016,395. The firm has a market cap of $103.14 billion, a PE ratio of -11.47, a PEG ratio of 2.07 and a beta of 0.38. The stock's fifty day moving average is $48.87 and its 200 day moving average is $54.88. Bristol-Myers Squibb has a 1 year low of $39.35 and a 1 year high of $63.33. The company has a debt-to-equity ratio of 2.90, a quick ratio of 1.15 and a current ratio of 1.25.

Bristol-Myers Squibb (NYSE:BMY - Get Free Report) last posted its quarterly earnings results on Thursday, April 24th. The biopharmaceutical company reported $1.80 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $1.50 by $0.30. Bristol-Myers Squibb had a positive return on equity of 13.93% and a negative net margin of 18.53%. The company had revenue of $11.20 billion for the quarter, compared to analyst estimates of $10.77 billion. During the same quarter last year, the company earned ($4.40) EPS. Bristol-Myers Squibb's revenue for the quarter was down 5.6% compared to the same quarter last year. As a group, equities research analysts forecast that Bristol-Myers Squibb will post 6.74 earnings per share for the current year.

Bristol-Myers Squibb Profile

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.